123 related articles for article (PubMed ID: 9699539)
1. M3/M21 serum levels in women with adnexal masses and inflammatory diseases.
Hefler L; Tempfer C; Heinzl H; Haeusler G; Steindl P; Schneeberger C; Gitsch G; Kainz C
Int J Cancer; 1998 Aug; 79(4):434-8. PubMed ID: 9699539
[TBL] [Abstract][Full Text] [Related]
2. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
3. CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases.
Tempfer C; Hefler L; Heinzl H; Loesch A; Gitsch G; Rumpold H; Kainz C
Br J Cancer; 1998 Oct; 78(8):1108-12. PubMed ID: 9792159
[TBL] [Abstract][Full Text] [Related]
4. Serum M3/M21 in ovarian cancer patients.
Tempfer C; Hefler L; Haeusler G; Sliutz G; Hanzal E; Reinthaller A; Kainz CH
Br J Cancer; 1997; 76(10):1387-9. PubMed ID: 9374388
[TBL] [Abstract][Full Text] [Related]
5. Serum M3/M21 in cervical cancer patients.
Sliutz G; Tempfer C; Hanzal E; Reinthaller A; Koelbl H; Zeillinger R; Kainz C
Eur J Cancer; 1997 May; 33(6):973-5. PubMed ID: 9291824
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and Management of Adnexal Masses.
Biggs WS; Marks ST
Am Fam Physician; 2016 Apr; 93(8):676-81. PubMed ID: 27175840
[TBL] [Abstract][Full Text] [Related]
7. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
8. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
Zheng H; Gao Y
Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
[TBL] [Abstract][Full Text] [Related]
10. CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.
Sagi-Dain L; Lavie O; Auslander R; Sagi S
Int J Biol Markers; 2015 Jul; 30(3):e333-40. PubMed ID: 25704505
[TBL] [Abstract][Full Text] [Related]
11. Serum C-reactive protein in the differential diagnosis of ovarian masses.
Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
[TBL] [Abstract][Full Text] [Related]
12. The serum tumor marker M3/M21 in the follow-up of breast cancer patients.
Tempfer C; Hanzal E; Zeillinger R; Koelbl H; Dadak C; Kainz C
Anticancer Res; 1996; 16(5B):3049-52. PubMed ID: 8920765
[TBL] [Abstract][Full Text] [Related]
13. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
[TBL] [Abstract][Full Text] [Related]
14. Serum soluble Fas levels in ovarian cancer.
Hefler L; Mayerhofer K; Nardi A; Reinthaller A; Kainz C; Tempfer C
Obstet Gynecol; 2000 Jul; 96(1):65-9. PubMed ID: 10862844
[TBL] [Abstract][Full Text] [Related]
15. Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses.
Reiser E; Aust S; Seebacher V; Reinthaller A; Helmy-Bader S; Schwameis R; Grimm C; Polterauer S
Gynecol Oncol; 2017 Dec; 147(3):690-694. PubMed ID: 28935270
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen.
Inaba N; Negishi Y; Fukasawa I; Okajima Y; Ota Y; Tanaka K; Matsui H; Iwasaki H; Sudo H; Tanaka N
Tumour Biol; 1995; 16(6):345-52. PubMed ID: 7569681
[TBL] [Abstract][Full Text] [Related]
17. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Czekierdowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
[TBL] [Abstract][Full Text] [Related]
18. Gamma-glutamyltransferase as a preoperative differential diagnostic marker in patients with adnexal mass.
Reiser E; Aust S; Seebacher V; Reinthaller A; von Mersi H; Schwameis R; Polterauer S; Grimm C; Helmy-Bader S
Eur J Obstet Gynecol Reprod Biol; 2019 Aug; 239():16-20. PubMed ID: 31158789
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
20. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
